LULULEMON/UN-FOUNDATION
8.10.2019 15:01:10 CEST | Business Wire | Press release
lululemon and the United Nations Foundation today announced their partnership around an innovative program to address the mental and physical health of UN development and humanitarian workers who serve on the front lines of urgent global challenges, so they can better support communities around the world. lululemon will commit $1 million USD over the next three years to Peace on Purpose, an evidence-based program, which provides access to mindfulness and self-care tools and resources for UN workers to build resilience in the face of adversity and stressful environments – such as responding to humanitarian emergencies, supporting communities facing poverty, and more. Peace on Purpose's mission is to equip aid workers with the tools to care for themselves so they can effectively care for others.
“lululemon and the UN Foundation share a commitment to building community and developing collaborative solutions for some of the world’s most pressing issues,” said Calvin McDonald, CEO of lululemon. “With increasing need for international humanitarian aid and peacekeeping, we want to cultivate the long-lasting benefits of mindfulness tools and sustain support for those whose mission is to serve others.”
“UN workers are on the front lines of global challenges, helping people in their times of greatest need,” said Kathy Calvin, President and CEO of the UN Foundation. “This work can often be stressful, and the UN has made it a priority to address the well-being of its people. Innovative partnerships like Peace on Purpose can support the UN workers who support the world. With lululemon’s support, we will be able to grow the program to help more UN staff care for themselves and for others.”
Peace on Purpose is a result of a three-year pilot led by lululemon’s Here to Be team and the UN Foundation, developed to address a series of issues, such as burnout, compassion fatigue, and stress-related physical, mental, and relational effects reported by UN staff members. Peace on Purpose has worked with UN agencies to build out trainings and workshops for more than 650 staff in US headquarters and seven additional countries – Jordan, Lebanon, Pakistan, South Sudan, Turkey, Turkmenistan and Zimbabwe.
Research that followed select trainings found that over half of the participants experienced a more than 40 percent improvement in overall well-being as seen in key psychological risk factors, such as work-related self-compassion, anxiety and depression, symptoms related to trauma, and feelings of distress.
Humanitarian aid workers report experiencing high rates of burnout, stress, and mental health stigmas in difficult global settings. Peace on Purpose’s curriculum introduces mindfulness tools as well-being resources to support current UN mental health programs. These tools – such as mindful breaths, emotion regulation, and yoga – can be implemented to meet the varying needs of UN staff in the diverse environments in which they operate.
With lululemon’s continued funding commitment and thought partnership, Peace on Purpose will aim to train 3,000 more UN development and humanitarian workers in-person over the next three years, build a hub of digital resources, and develop condensed trainings and curriculum translations to reach an additional 30,000 UN staff.
Peace on Purpose is a key element of lululemon’s commitment to social impact and sustainability. The company’s Impact Agenda is comprised of three elements – Be Human, Be Well and Be Planet – to support and accelerate meaningful positive impact around the world.
To learn more about Peace on Purpose or lululemon’s Global Impact Agenda, including Here to Be, visit https://shop.lululemon.com/story/sustainability .
About lululemon athletica inc.
lululemon athletica inc. (NASDAQ:LULU) is a healthy lifestyle inspired athletic apparel company for yoga, running, training, and most other sweaty pursuits, creating transformational products and experiences which enable people to live a life they love. Setting the bar in technical fabrics and functional designs, lululemon works with yogis and athletes in local communities for continuous research and product feedback. For more information, visit www.lululemon.com
.
About the United Nations Foundation
The United Nations Foundation acts as a strategic partner to help the United Nations mobilize the ideas, people, and resources it needs to drive global progress and tackle urgent challenges. We focus on issues at the heart of the Sustainable Development Goals, build initiatives across sectors to solve problems at scale, and engage citizens who seek action. Founded in 1998 by entrepreneur and philanthropist Ted Turner, the UN Foundation works with philanthropic, corporate, government, and individual partners. Learn more at www.unfoundation.org
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191008005308/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom